PureTech Health

Founder and CEO Daphne Zohar leads all strategic and capital allocation decisions, with President Bharatt Chowrira overseeing business operations, strategy, and the Founded Entities portfolio. Co-founder Robert Langer, an MIT Institute Professor and prolific biotech inventor, plays a central role in scientific evaluation and origination but does not hold an executive management position. The firm's board includes directors with public-company and drug-development experience who govern the capital allocation framework.

PureTech sources primarily through its deep ties to top-tier academic research institutions, particularly MIT and Harvard, leveraging Robert Langer's lab network and the broader Boston biotech ecosystem. The firm evaluates hundreds of early-stage programs annually, looking for novel biological mechanisms with strong preclinical data where its internal drug-development team can materially accelerate translation. The London Stock Exchange listing provides a public-vehicle mechanism for deal origination that academic founders sometimes find more aligned with long-term science goals than traditional venture capital.

PureTech is neither. It is a publicly traded clinical-stage biotherapeutics company listed on the London Stock Exchange that functions as a venture-creation platform. It originates companies around specific drug-development programs, retains material equity stakes, and provides centralized R&D and management resources. Its capital comes from public equity markets rather than from a single family or a closed limited-partner fund, giving it a permanent-capital structure more akin to a holding company.

Karuna Therapeutics, founded by PureTech in 2011 and taken public in 2019, was acquired by Bristol Myers Squibb for $14 billion in December 2023 — the largest pure-play neuroscience acquisition in recent years. Karuna's lead asset, KarXT (now branded Cobenfy), became the first FDA-approved schizophrenia treatment with a novel mechanism of action in decades. PureTech retained a significant equity stake through the acquisition and continues to hold a royalty interest in the approved product.

PureTech created each Founded Entity as a separate legal company with its own management team, board, and capitalization structure. PureTech maintains majority or significant minority equity ownership in these entities, appoints board representatives, and provides shared access to its drug-development and regulatory expertise. The entities pursue independent financing strategies — including IPOs and partner deals — while PureTech consolidates their performance into its own financial reporting and receives dividends or exit proceeds when stakes are monetized.

Structurally it most closely resembles a hybrid: it employs the venture-creation model of founding and capitalizing companies around individual programs, but operates from a permanent-capital public-company balance sheet with in-house clinical development and regulatory capabilities more typical of a biopharma firm. Unlike a fund, it does not have a obligated return-of-capital cycle; unlike a pharma company, it typically monetizes individual programs through affiliate sales or licensing rather than building out a commercial salesforce. The model is sometimes called a 'biotech platform company' or 'venture foundry.'

The firm concentrates on neuroscience, immunology, and the brain-immune-gut axis, with active programs in Idiopathic Pulmonary Fibrosis, lymphatic disorders, gastrointestinal indications, and neuropsychiatric conditions. It also maintains exposure to digital therapeutics and medical devices through Founded Entities like Akili Interactive and Gelesis. PureTech has publicly communicated a strategic priority around wholly owned clinical-stage programs alongside the Founded Entities portfolio, effectively operating two parallel pipelines.